Research Analysts Set Expectations for VIR FY2025 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Vir Biotechnology in a research note issued on Tuesday, December 30th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($2.98) per share for the year, up from their previous estimate of ($3.45). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.40) EPS and FY2029 earnings at ($1.13) EPS.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $1.98 million. During the same quarter in the prior year, the business earned ($1.56) EPS. The business’s revenue was up .8% compared to the same quarter last year.

VIR has been the subject of a number of other research reports. Evercore ISI initiated coverage on Vir Biotechnology in a report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.30.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $6.03 on Thursday. The stock has a market cap of $838.89 million, a PE ratio of -1.67 and a beta of 1.34. Vir Biotechnology has a 52-week low of $4.16 and a 52-week high of $14.45. The firm has a 50-day moving average of $5.99 and a 200-day moving average of $5.51.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in shares of Vir Biotechnology in the 3rd quarter worth approximately $38,000. Raymond James Financial Inc. purchased a new stake in shares of Vir Biotechnology during the second quarter valued at $35,000. Federated Hermes Inc. grew its position in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares during the period. Apollon Wealth Management LLC bought a new stake in shares of Vir Biotechnology in the second quarter worth $50,000. Finally, Truist Financial Corp bought a new stake in shares of Vir Biotechnology during the 3rd quarter valued at about $63,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, CFO Jason O’byrne sold 6,799 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $5.56, for a total value of $37,802.44. Following the transaction, the chief financial officer directly owned 110,701 shares of the company’s stock, valued at approximately $615,497.56. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $6.00, for a total value of $132,000.00. Following the completion of the transaction, the director owned 1,188,391 shares in the company, valued at approximately $7,130,346. The trade was a 1.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 3,009,666 shares of company stock worth $18,163,565. Insiders own 16.00% of the company’s stock.

Key Stores Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright raised several 2025–2026 quarterly and full‑year EPS estimates (notably Q4 2025 from ($0.59) to ($0.13), and FY2026 from ($2.40) to ($2.16)), signaling improved visibility on near‑term losses and better-than-expected trajectory. The firm kept a “Buy” rating and a $15 target, implying meaningful upside vs. current levels.
• Positive Sentiment: Analyst P. Trucchio also trimmed losses across Q1–Q4 2026 and issued progressive multi‑year EPS forecasts through FY2029 (e.g., FY2027–FY2029 progressively less negative), suggesting expectations for improving margins over time.
• Neutral Sentiment: Media roundup: an MSN piece listed “3 ‘Strong Buy’ stocks to buy now” — investors may interpret inclusion in analyst roundup as supportive, though check the article for context and which analysts/picks are cited. 3 ‘Strong Buy’ stocks to buy now
• Negative Sentiment: Fundamentals remain a risk: recent quarterly results showed a substantial EPS miss and the company is still loss‑making (consensus FY currently deeply negative). Upside from analyst revisions is tempered by continued negative net margin and execution/clinical risk inherent to biotech development.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.